Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(04): 455-456
DOI: 10.4103/wjnm.WJNM_110_20
Interesting Cases

18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection

Siroos Mirzaei
Department of Nuclear Medicine with PET-Center, Klinik Ottakring, Vienna, Austria
,
Cherin Farhan
Department of Nuclear Medicine with PET-Center, Klinik Ottakring, Vienna, Austria
,
Mario Karolyi
1   Department for Infectious Diseases and Tropical Medicine, Klinik Favoriten (KFJ), Vienna, Austria
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The COVID-19 pandemic has now reached most countries. However, the referred patients to a nuclear medicine department will be primarily the asymptomatic ones. We report the case of a patient (84-year-old male) who was sent for 18F-prostate-specific membrane antigen positron emission tomography computed tomography (PSMA PET-CT) with suspicion of recurrent disease after prostate cancer and total prostatectomy 2 years prior to the examination. He suffered from COVID-19 pneumonia 4 weeks prior to PET-CT examination. The 18F-PSMA PET-CT revealed moderate elevated uptake in the area of previous pneumonia in the right lung. The radiological findings showed ground glass changes in this area indicating possible residual inflammatory disease even weeks after infection.

Keywords

18F-prostate-specific membrane antigen - COVID-19 - infection - positron emission tomography computed tomography - prostate cancer

Financial support and sponsorship

Nil.




Publication History

Received: 08 August 2020

Accepted: 23 August 2020

Article published online:
19 April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Czernin J, Fanti S, Meyer PT, Allen-Auerbach M, Hacker M, Sathekge M, et al. Imaging clinic operations in the times of COVID-19: Strategies, Precautions and Experiences. J Nucl Med 2020;47:2038-9..
  • 2 Paez D, Gnanasegaran G, Fanti S, Bomanji J, Hacker M, Sathekge M, et al. COVID-19 pandemic: Guidance for nuclear medicine departments. Eur J Nucl Med Mol Imaging 2020;47:1615-9.
  • 3 Setti L, Kirienko M, Dalto SC, Bonacina M, Bombardieri E. FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients. Eur J Nucl Med Mol Imaging 2020;47:1649-56.
  • 4 Grubmüller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, et al. (64) Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies. Cancer Biother Radiopharm 2016;31:277-86.
  • 5 Sharif-Paghaleh E, Yap ML, Puh SL, Adam Badar A, Torres JB, Chuamsaamarkkee K, Kampmeier F, et al. Non-invasive whole-body detection of complement activation using radionuclide imaging in a mouse model of myocardial ischaemia-reperfusion injury. Sci Rep 2018;8:4687.